Jian Chen1, Meng-xiong Sun, Ying-qi Hua, Zheng-dong Cai. 1. Department of Orthopaedics, Shanghai First People's Hospital, Nanjing Medical University, Shanghai, 200072, China, chenjianpumch@163.com.
Abstract
BACKGROUND: A number of studies have investigated the role of serum lactate dehydrogenase (LDH) level in patients with osteosarcoma but have yielded inconsistent and inconclusive results. Thus, we conducted a meta-analysis to assess its prognostic value more precisely. METHODS: Systematic computerized searches of PubMed, Embase and Web of Science databases were performed. The pooled hazard ratio (HR) with 95 % confidence intervals (95 % CI) of overall survival was used to assess the prognostic role of serum LDH level. RESULTS: Ten studies published between 1997 and 2013 with a total of 943 osteosarcoma patients were included. Overall, the pooled HR for all ten eligible studies evaluating high LDH level on overall survival was 1.92(95 % CI 1.53-2.40). Sensitivity analysis suggested that the pooled HR was stable and omitting a single study did not change the significance of the pooled HR. Funnel plots and Egger's tests revealed there was some possibility of publication bias risk in the meta-analysis. CONCLUSION: This meta-analysis shows that high serum LDH level is obviously associated with lower overall survival rate in patients with osteosarcoma, and it is an effective biomarker of prognosis.
BACKGROUND: A number of studies have investigated the role of serum lactate dehydrogenase (LDH) level in patients with osteosarcoma but have yielded inconsistent and inconclusive results. Thus, we conducted a meta-analysis to assess its prognostic value more precisely. METHODS: Systematic computerized searches of PubMed, Embase and Web of Science databases were performed. The pooled hazard ratio (HR) with 95 % confidence intervals (95 % CI) of overall survival was used to assess the prognostic role of serum LDH level. RESULTS: Ten studies published between 1997 and 2013 with a total of 943 osteosarcomapatients were included. Overall, the pooled HR for all ten eligible studies evaluating high LDH level on overall survival was 1.92(95 % CI 1.53-2.40). Sensitivity analysis suggested that the pooled HR was stable and omitting a single study did not change the significance of the pooled HR. Funnel plots and Egger's tests revealed there was some possibility of publication bias risk in the meta-analysis. CONCLUSION: This meta-analysis shows that high serum LDH level is obviously associated with lower overall survival rate in patients with osteosarcoma, and it is an effective biomarker of prognosis.
Authors: Alexander J Chou; Eugenie S Kleinerman; Mark D Krailo; Zhengjia Chen; Donna L Betcher; John H Healey; Ernest U Conrad; Michael L Nieder; Michael A Weiner; Robert J Wells; Richard B Womer; Paul A Meyers Journal: Cancer Date: 2009-11-15 Impact factor: 6.860
Authors: Allen M Goorin; Douglas J Schwartzentruber; Meenakshi Devidas; Mark C Gebhardt; Alberto G Ayala; Michael B Harris; Lee J Helman; Holcombe E Grier; Michael P Link Journal: J Clin Oncol Date: 2003-04-15 Impact factor: 44.544
Authors: R García; J M Hernández; M D Caballero; M González; J Galende; M C del Cañizo; L Vázquez; J F San Miguel Journal: Br J Cancer Date: 1993-12 Impact factor: 7.640
Authors: Ricardo J Flores; Aaron J Kelly; Yiting Li; Manjula Nakka; Donald A Barkauskas; Mark Krailo; Lisa L Wang; Laszlo Perlaky; Ching C Lau; M John Hicks; Tsz-Kwong Man Journal: Cancer Date: 2016-08-16 Impact factor: 6.860